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Introduction
Mosquitoes transmit pathogens and parasites that cause diseases that adversely affect human health worldwide including malaria, yellow fever, and dengue. Existing approaches for mosquito control have demonstrated efficacy in reducing incidences of such diseases, but are becoming inadequate due to the emergence of insecticide-resistant mosquito populations (Hemingway, 2014; Hemingway and Ranson, 2000) . The need for novel mode-of-action compounds to control mosquitoes is further emphasized by the fact that it has been several decades since a new public health insecticide has been deployed to reduce the spread of vectorborne diseases (Hemingway et al., 2006) .
Arthropod G protein-coupled receptors (GPCRs) mediate critical biological processes (Hauser et al., 2006) and have emerged as potential insecticide targets (Hill et al., 2013) .
Molecular approaches, including genome sequencing efforts, have identified more than 100
GPCRs within the genomes of several arthropod vector species (Arensburger et al., 2010; Hill et al., 2002; Kirkness et al., 2010; Nene et al., 2007) . Among the GPCR superfamily, the biogenic amine receptors are of particular interest because of their crucial roles in insect physiology and behavior (Fuchs et al., 2014; Hauser et al., 2006) . For example, the biogenic amine, dopamine, and its receptors are implicated in a variety of arthropod behaviors including arousal (Kume et al., 2005) , locomotion (Draper et al., 2007; Mustard et al., 2010; Yellman et al., 1997) , and olfactory learning (Kim et al., 2007; Riemensperger et al., 2011) . It is also notable that dopamine is associated with salivary function of vectors (Ali, 1997; Sauer et al., 2000; Simo et al., 2014; Simo et al., 2011) , suggesting potential roles for the mediation of pathogen acquisition and transmission during blood feeding. In Aedes aegypti, dopamine is also implicated in sclerotization and ovarian/egg development, as increased dopamine levels were observed in JPET #219717 6 newly emerged adults and also following a blood meal (Andersen et al., 2006) . The central roles of dopamine systems in fundamental biological processes offer the dopamine receptors as potential insecticide targets.
A recent study from our invertebrate receptor group supports the pursuit of D1-like dopamine receptors (AaDOP1 and AaDOP2) from the yellow fever mosquito, A. aegypti, as targets for novel mode-of-action insecticides (Meyer et al., 2012) . Specifically, AaDOP2 was utilized as a prototypical target for a "genome-to-lead" approach for the discovery of targetbased insecticides, where genomic sequence data were used to drive in vitro functional characterization of recombinant AaDOP receptors in HEK293 cells (Meyer et al., 2012) .
Following pharmacological characterization, high-throughput screening (HTS)-amenable evaluation of pharmacologically-active compounds identified AaDOP2 antagonists that display significant in vivo toxicity to mosquito larvae (Meyer et al., 2012) , supporting the validity of targeting AaDOP2 for A. aegypti control.
The present study entailed a robust follow-up pharmacological analysis of AaDOP2 antagonists identified in a small molecule screen of the LOPAC 1280 library (Meyer et al., 2012) .
To accomplish this, we developed an HTS-amenable cell-based assay that enabled an in-depth study of AaDOP2 antagonism by tricyclic antidepressants and structurally-related compounds.
Several of these compounds demonstrated enhanced potency for in vitro AaDOP2 antagonism and greater efficacy for larval death in mosquito bioassays. Importantly, we provided evidence that several AaDOP2 antagonists caused toxicity to adult A. aegypti. Furthermore, we improved upon our previously described genome-to-lead pipeline via implementation of efficiencyenhancing in vivo assay technologies.
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Materials and Methods
Materials
Cis-(Z)-flupenthixol, clozapine, mianserin, nortriptyline, imipramine, protriptyline, norclomipramine, pirenperone, desipramine, haloperidol, trazodone, fluoxetine, fluvoxamine, buspirone, (+)-butaclamol, amoxapine, amitriptyline, chlorpromazine, doxepin, loratadine, ketotifen, chlorprothixene, loxapine, cyproheptadine, asenapine, diphenhydramine, ritanserin, ketanserin, risperidone, 3-isobutyl-1-methylxanthine (IBMX), G418, and Dulbecco's modified Eagle's medium (DMEM) were purchased from Sigma-Aldrich (St. Louis, MO). Amperozide, methiothepin, clomipramine, SCH-23390, LY-310,762, R59-022, and tomoxetine were purchased from Tocris Bioscience (Ellisville, MO). Benztropine was purchased from Enzo Life Sciences (Farmingdale, NY). The antibiotic-antimycotic 100x solution was purchased from Life Technologies (Grand Island, NY). FetalClone I serum, bovine calf serum, HEPES, and Hank's balanced salt solution (HBSS) were purchased from Hyclone (Logan, UT). The HTRF cAMP kit was purchased from Cisbio Bioassays (Bedford, MA).
Cisbio homogenous time-resolved fluorescence (HTRF) cAMP dynamic 2 cell-based assay
HEK293 cells stably expressing AaDOP2 (HEK-AaDOP2) or the human D 1 dopamine receptor (HEK-hD 1 ) were maintained and cryogenically frozen as previously described (Meyer et al., 2012) . To prepare for pharmacological analysis, cells were thawed and re-suspended in assay buffer (HBSS, 20 mM HEPES, 0.1% Fatty acid free bovine serum albumin). To remove cryogenic freezing media, cell suspensions were centrifuged at 500xg for 5 min, followed by aspiration of the supernatant. Cell pellets were re-suspended in assay buffer and seeded into 384-well plates (Perkin Elmer CulturPlate-384) at 2,000-2,500 cells per well and incubated at JPET #219717 8 37°C and 5% CO 2 for 1 h. Test compounds were added using a 384-well pin tool (V&P Scientific). A MultiFlo (BioTek) low-volume bulk reagent dispenser was used to dispense 3 μ M dopamine (in assay buffer containing 500 μ M IBMX and 0.02% ascorbic acid) to activate AaDOP2. Drug stimulation was carried out at room temperature for 1 h. Cells were lysed by sequential addition of cAMP-d2 and anti-cAMP cryptate conjugate, both diluted 1:39 in lysis buffer and were incubated at room temperature for 1 h. Time-resolved fluorescence resonance energy transfer (TR-FRET) was measured with a lag time of 100 μ s and integration time of 300 μ s using a Synergy4 (BioTek) fluorescence plate reader with a 330/80 nm excitation filter and emission filters of 620/10 nm and 665/8 nm. Sensitivity parameters were set by reading the cAMP standard curve using the autosensitivity setting. All experimental conditions were read using sensitivity settings obtained for the cAMP standard curve. Cellular cAMP concentrations were estimated in GraphPad Prism by applying the 620/665 nm fluorescence ratio values to a standard curve of known cAMP concentrations.
Cyclic AMP measurements in HEK293 cells stably expressing the human D 1 dopamine receptor were performed as described above, but 500 nM dopamine was used to stimulate cAMP accumulation.
In vivo Aedes aegypti larval screen.
Test compounds were evaluated for in vivo toxicity in bioassays against L3 stage A.
aegypti larvae in a double-blind manner. Briefly, compounds were re-suspended in water and added to wells of a 24-well plate (BD Bioscience, San Jose, CA) in duplicate, with each well containing five A. aegypti larvae in 1 ml total volume to achieve a final concentration of 400 μM per well (See Supplemental Figure 1 for illustrations of the assay format). Plates were incubated JPET #219717 9 at 22°C, and the assay was scored for larval mortality at 24, 48, and 72 h. Larvae unresponsive to gentle tapping of the plate or touch with a sterile probe were scored as dead.
Aedes aegypti adult CRCs.
Test compounds were dissolved in deionized water to a 200 mM stock concentration and serially diluted in Aedes saline (Hayes, 1953) to achieve a dose range of 0.25 -20 mM. Fourday-old A. aegypti adult females [average wing length of 3.4 mm, measured as described by Briegel (1990) ] were anesthetized on ice and groups of 20 females were injected per dilution of test compound (0.5 μ l per mosquito) or Aedes saline alone (control) using a pulled glass capillary needle. Additional un-injected mosquito controls were also included. Mosquitoes were housed in 10 cm diameter x 20 cm height paper coffee cup cages with lace screen (secured with rubber bands) and maintained at 75% humidity with 10% sucrose provided ad libitum via a cotton wick (See Supplemental Figure 2 for illustrations of injections and mosquito housing). Observations of mortality were made daily for up to 4 d post treatment. Mosquitoes were scored as "dead" if no movement was observed and confirmed by no response to a gentle touch of the legs with a metal probe. When observed at any time point, moribund adult mosquitoes (i.e., insects incapable of standing, walking, or flying) were scored as dead. At the 24 hour time point, and to a lesser extent at the 48 hour time point, we observed a percentage of the adult mosquito population that was moribund. These individuals did not recover and died by assay end-point.
The moribund phenotype was negligible at 96 hours (less than 1% of the adult population for any replicate dose). LD 50 values for test compounds injected into adult mosquitoes were calculated by non-linear regression using the sigmoidal dose-response equation in the GraphPad Prism software. representing other classes of antidepressants displayed less than 10% inhibition at 3 μ M ( Figure   1 and Table 1 ).
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Results
In vitro evaluation of
To identify novel AaDOP2 antagonists with chemical structures distinct from the tricyclic antidepressant ring scaffold, we evaluated concentration-dependent effects of a suite of additional active compounds identified in our previous small molecule screen (Meyer et al., 2012) together with structurally-related compounds, enabling an initial in vitro SAR analysis.
As performed above, test compounds were studied for their ability to modulate dopaminestimulated (3 µM) cAMP accumulation in HEK-AaDOP2 cells (Table 2) . Interestingly, six compounds were more potent antagonists than the prototypical AaDOP2 antagonist, amitriptyline (Table 2) . Furthermore, asenapine, methiothepin, and cis-(Z)-flupenthixol displayed sub-nanomolar IC 50 values for inhibition of dopamine-stimulated cAMP in HEKAaDOP2 cells (Table 2) .
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Pharmacological selectivity for the targeted insect over humans and other animals is a critical attribute of potential insecticides. To address this concern, several of the most potent (Table 3 ). However, in contrast to the hD 1 -selective antagonist SCH-23390, all of these compounds were more potent antagonists of AaDOP2 than hD 1 , suggesting potential species-selective pharmacological profiles for these compounds.
In vivo toxicity of AaDOP2 antagonists: Effects on Aedes aegypti larvae.
An important second step in our insecticide discovery effort was the evaluation of the in vivo activity of compounds identified and characterized in the cell-based in vitro studies. We developed an A. aegypti larval screen that can be performed in 24-well plate format, allowing rapid assessment of in vivo toxicity for compounds identified as potent antagonists in the in vitro studies. This assay was designed to also enable evaluation of speed-to-kill and support prioritization of compounds for further study. Twenty-five compounds were tested using this approach (Table 4) , and 10 compounds (asenapine, chlorpromazine, benztropine, methiothepin, cis-(Z)-flupenthixol, chlorprothixene, loxapine, mianserin, amperozide and clomipramine) caused 70-100% larval mortality within 24 hours post-treatment. These compounds were fasteracting and caused greater mortality of mosquito larvae at the 24 hour treatment time-point than our previously identified lead compound for insecticide development, amitriptyline. Notably, asenapine, chlorpromazine, and amperozide caused greater than 70% mortality of the mosquito This article has not been copyedited and formatted. The final version may differ from this version. 13 population within 30 minutes, and cis-(Z)-flupenthixol, chlorprothixene, mianserin, loxapine and methiothepin caused greater than 70% mortality within three hours (data not shown). We also identified five compounds with moderate mosquito toxicity (i.e., 40-70% mortality at 24 hours post exposure), and nine compounds with limited or no toxicity to mosquito larvae (i.e., 0-40% mortality at 24 hours) ( Table 4) bioassay were assessed for toxicity (LD 50 ) and speed-to-kill in adult mosquito bioassays ( Figure   3 and Table 5 ). All compounds tested caused dose-dependent toxicity to adult A. aegypti and were capable of providing 100% mortality at all time-points, whereas <6% mortality was 14 amperozide remained relatively stable over the same treatment duration, suggesting that these compounds reach their maximum potency earlier than chlorpromazine and cis-(Z)-flupenthixol (Table 5) .
This article has not been copyedited and formatted. The final version may differ from this version. antagonists and the toxicity of these compounds to mosquito larvae in vivo (Figure 2 ). However, it should be noted that benztropine and amperozide, which caused rapid and high larval mortality (Arnt and Skarsfeldt, 1998; Bolden et al., 1992; Kanba and Richelson, 1984; U'Prichard et al., 1977) , suggesting the possibility that modulation of additional A. aegypti GPCRs could contribute to the in vivo toxicity of these compounds. Alternatively, such differences between the in vitro potency and the magnitude of in vivo toxicity for a given compound may reflect complex factors that impact in vivo insecticidal activity, including differences in the physic-chemical properties of compounds that affect absorption through the insect cuticle, dissemination through insect tissues to the target site, and detoxification by insect gut and hemolymph enzymes. Nonetheless, the correlation between the in vitro potencies for AaDOP2 antagonism and larval toxicities suggests that optimizing compounds for potency and selectivity in vitro may be an efficient way to identify and prioritize new lead compounds.
The in vitro evaluation of the chosen compounds for modulation of AaDOP2 provided preliminary insight into the relationship between chemical structure and the potency of AaDOP2 antagonism. One SAR trend suggests that conformational rigidity contributes to the potency of AaDOP2 antagonists. For example, compounds with 6-or 7-membered central rings were generally the most potent AaDOP2 antagonists (Tables 1 and 2 and Supplemental Figure 3) .
However, the moderate potency of R59-022, risperidone, benztropine, and amperozide (IC 50 values ranging from 53-570 nM) indicate that the central ring is not essential for antagonist activity. Benztropine was ~22-fold more potent than diphenhydramine, suggesting that conformational control of the amine moiety also contributes to the potency of compounds with no central ring ( Figure 4A ). Another SAR trend suggested that greater lipophilicity may enhance Figure 4B ). Furthermore, ligands with tertiary amines (clomipramine, imipramine, amitriptyline, and loxapine) were ~5-100-fold more potent than the secondary amine analogs of these compounds (norclomipramine, desipramine, nortiptyline, and amoxapine, respectively), demonstrating the influence of amine-state on AaDOP2 antagonist potency ( Figure   4C and Supplemental Figure 3) . Also, clomipramine and norclomipramine displayed ~5-6 fold more potent IC 50 values than imipramine and desipramine, respectively, suggesting that halide substituents of aromatic rings within the tricyclic core can increase the potency of the identified antagonists ( Figure 4C ). Enhancements in AaDOP2 antagonist potency were also apparent when considering combinations of chemical properties such as lipophilicity and halide substitution ( Figure 4C , clomipramine vs. desipramine) or lipophilicity and conformational rigidity ( Figure   4D ). The chemical scaffolds identified above and their key structural features that contribute to AaDOP2 antagonism may be utilized to guide further lead optimization studies.
The in vitro and in vivo data presented here support the hypothesis that targeting GPCRmediated processes is a viable strategy for identifying insecticidal compounds. However, a major challenge associated with this approach is the development of ligands that are selective for disruption of biological activity in A. aegypti but not in humans or other higher eukaryotes. To date, all reports of compounds that display both AaDOP2 antagonism and in vivo efficacy are known to have biological activity in humans. Our studies identified compounds that are highly selective for targeting AaDOP2 receptors over the human D 1 dopamine receptor (Table 3) 18 cell-based in vitro assays to screen against panels of human GPCRs. Also, virtual or in silico screening methods are emerging as promising approaches for the study of GPCR modulators (Shoichet and Kobilka, 2012) . Such computational methodologies for lead optimization of antipsychotics and tricyclic antidepressants are strengthened by recently reported human GPCR crystal structures from histamine (Shimamura et al., 2011) , serotonin (Wang et al., 2013) , dopamine (Chien et al., 2010) , adrenergic (Rasmussen et al., 2007; Warne et al., 2008) , and muscarinic (Haga et al., 2012; Kruse et al., 2012) receptor families. The combination of these in vitro and in silico approaches is expected to provide insight into the molecular determinants of selectivity for AaDOP2 versus human GPCRs and may ultimately produce mosquito GPCRselective small molecules.
Pharmacological selectivity considerations are multi-fold, as ligand selectivity for
AaDOP2 receptors over non-target insects (e.g., honeybees), in addition to selectivity over human GPCRs, is also paramount. Pharmacological screening panels can be assembled for invertebrate targets to better understand ligand pharmacology at these receptors. For example, cross-species comparative pharmacological studies of invertebrate dopamine receptor modulation can be expanded to include GPCRs from non-target insects. Furthermore, upon genome-mining and cloning of additional biogenic amine receptors (in addition to AaDOP1 and AaDOP2), AaDOP2 antagonists can be screened for modulation of other A. aegypti GPCRs including muscarinic acetylcholine, serotonin, and octopamine/tyramine receptors (Nene et al., 2007) . These pharmacological efforts are expected to provide a deeper understanding of small molecule modulation of invertebrate GPCRs and may ultimately allow for target-based pesticide discovery efforts related to other pest arthropods.
This article has not been copyedited and formatted. The final version may differ from this version. (Table 4) to rapidly assess larval toxicity and the utilization of an injection assay to evaluate toxicity in adult A. aegypti.
In addition to the antipsychotic and tricyclic antidepressant lead optimization and GPCR profiling studies suggested above, HTS of diverse small molecule libraries for the identification of AaDOP2 modulators with novel chemical scaffolds may also be a fruitful endeavor.
Especially enticing is the possibility of screening for allosteric modulators of AaDOP2 receptors, as drug discovery campaigns targeting multiple human GPCRs have identified allosteric modulators with unmatched specificity and selectivity (Conn et al., 2009; Wootten et al., 2013) .
Allosteric modulators are attractive because the orthosteric sites (i.e., the sites of endogenous values (nmol/mosquito) were calculated from dead and moribund mosquitoes and represent the mean ± S.E.M. of three independent experiments. The average percent mortality was less than 6% for both injected and un-injected controls throughout the experiment. 
Compound
